A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...
Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...
When looking back at one of the most disruptive years in biopharma in recent memory, sev | Drug pricing, layoffs, personnel moves and other topics drove reader interest all year long. Here's a look at ...
Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...
Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity
After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback